Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin Modulation of fMRI Connectivity and Food Reward
NCT02982551Phase 1Withdrawn
- Sponsor
- University of Pittsburgh
- Start
- Jan 2016
- Primary completion
- Dec 2017
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of Humulin R + Kanglaite Injection, sponsored by University of Pittsburgh. Primary endpoint: fMRI Blood Oxygen Level Dependent Response at 14 minutes. Planned start Jan 2016; status: withdrawn.
02
Drugs
Humulin R + Kanglaite Injection
Beyond the preview
Go deeper on NCT02982551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02982551.